Menu

COPD hero image

Chronic Obstructive Pulmonary Disease (COPD) is a common, treatable chronic lung disease that causes obstructed airflow from the lungs.

  • UK population
    >3,000,000 people are estimated to have COPD in the UK 1
  • Magnifying glass
    However 2,000,000 of these remain undiagnosed 1
  • Medical
    COPD is a common cause of death in the UK with about 29,000 deaths a year in England and Wales 2

Untreated, COPD can lead to a fast progression of disease, heart problems, and worsening respiratory infections. However, with the right diagnosis and treatment, patients may breathe better, enjoy life and live for many years.

What treatments do GSK offer for patients with COPD?

Pack shot

Anoro▼ Ellipta (umeclidinium/vilanterol) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Discover Anoro

Anoro Ellipta Prescribing Information (pdf)

Pack shot

Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol) is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA.

Discover Trelegy

Trelegy Ellipta Prescribing Information (pdf)

Get Started

Access the CAT pad

Assess the impact COPD is having on your patients’ lives by using the COPD Assessment Test (CAT).

ACCESS HERE

Free resources

Need an Ellipta training inhaler? Or simply looking for some patient resources on COPD? Then this is the place for you.

View all Resources

Request a contact

Learn about our COPD treatment options from one of our representatives.

Enquire now

Hear from the experts

From diagnosis to review, explore expert led content to help you give COPD patients the right treatment.

Explore page

References

  1. National Institute for Health and Care Excellence, COPD 2019. Available at https://cks.nice.org.uk/chronic-obstructive-pulmonary-disease#!backgroundSub:1 [Accessed May 2022].
  2. ONS, Deaths from asthma and COPD, England & Wales, 2001 to 2017 https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/adhocs/009602deathsfromasthmaandcopdenglandandwales2001to2017byoccurrence (Accessed May 2022)

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

October 2022 | PM-GB-UCV-WCNT-200004 (V3.0)